R Statistical Software in the Application of Continual Reassessment Method for Phase Ⅰ Clinical Trial of Anti-cancer Drug
HUANG Ya-fang and
School of General Practice and Continuing Education,Capital Medical University,Department Clinical Research,Inselspital,University of Bern,Murtenstrasse ,,Bern,Switzerland
[1]Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology [J]. Nat Rev Clin Oncol, 2016,13(2):106-117.
[2]Paoletti X, Ezzalfani M, Le Tourneau C. Statistical controversies in clinical research:requiem for the 3 + 3 design for phase I trials [J]. Ann Oncol, 2015,26(9):1808-1812.
[3]Conaway MR, Petroni GR. The impact of early-phase trial design in the drug development process [J]. Clin Cancer Res, 2019,25(2):819-827.
[4]O′Quigley J, Pepe M, Fisher L. Continual reassessment method:a practical design for phase 1 clinical trials in cancer [J]. Biometrics, 1990,46(1):33-48.
[5]O′Quigley J, Shen LZ. Continual reassessment method:a likelihood approach [J]. Biometrics, 1996,52(2):673-684.
[6]Bove DS, Yeung WY, Palermo G, et al. crmPack:object-oriented implementation of CRM designs [S]. CRAN, Available at:http://cran.r-project.org/web/packages/crmPack/index.html. Accessed 14 Jun 2019.
[7]Steeting M, Mander A, Sabin T. Bcrm:Bayesian continual reassessment method designs for phase I dose-finding trial [J]. J Stat Softw, 2013,54(13):1-26.
[8]黄亚芳, 谢文杰. 抗癌药Ⅰ期临床试验连续重评估方法解析及应用 [J]. 中国药物评价, 2019,36(1):46-52.
[9]Polley MY. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities [J]. Stat Med, 2011,30(17):2130-2143.
[10]Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials [J]. Stat Med, 2017,36(2):266-279.
[11]Wheeler GM, Mander AP, Bedding A, et al. How to design a dose-finding study using the continual reassessment method [J]. BMC Med Res Methodol, 2019,19(1):18.
[12]O′Quigley J, Reiner E. A stopping rule for the continual reassessment method [J]. Biometrika, 1998,85(3):741-748.
[13]O′Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials:a review and results of a Monte Carlo study [J]. Stat Med, 1991,10(11):1647-1664.
[14]Storer BE. Design and analysis of phase I clinical trials [J]. Biometrics, 1989,45(3):925-937.
[15]Yap C, Billingham LJ, Cheung YK, et al. Dose transition pathways:the missing link between complex dose-finding designs and simple decision-making [J]. Clin Cancer Res, 2017,23(24):7440-7447.
[16]Wages NA, Petroni GR. A web tool for designing and conducting phase I trials using the continual reassessment method [J]. BMC Cancer, 2018,18(1):133.